BrainsWay (NASDAQ:BWAY) Releases Earnings Results

BrainsWay (NASDAQ:BWAY) posted its earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03, Zacks reports. The business had revenue of $10.50 million for the quarter, compared to analyst estimates of $10.07 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.56%. During the same period in the prior year, the company posted ($0.01) EPS. BrainsWay updated its FY 2024 guidance to EPS.

BrainsWay Stock Up 1.1 %

NASDAQ BWAY traded up $0.10 during trading on Thursday, hitting $9.14. The stock had a trading volume of 14,347 shares, compared to its average volume of 95,521. The company has a market capitalization of $152.44 million, a PE ratio of 90.40 and a beta of 1.25. BrainsWay has a twelve month low of $4.16 and a twelve month high of $10.98. The firm has a 50 day moving average price of $9.16 and a 200 day moving average price of $7.44.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BWAY shares. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of BrainsWay in a research note on Monday, October 21st. Northland Securities upped their price objective on shares of BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.